Listen to this article · 7 min listen

The whole AI in healthcare field is moving at a breakneck speed, pushed along by new tech and the constant pressure for better efficiency and patient results. If you’re trying to track companies in this space, especially using a framework like the AI Health 100 methodology, you have to get one thing straight: the difference between what people expect to happen in the market and the hard growth metrics you can actually count. This is a look at how leader expectations, like the ones in a new Innovaccer survey, do (or don’t) line up with the concrete ranking criteria that separate the fastest growing AI health companies from the pack.

Innovaccer’s Survey: Anticipating AI Maturity in Healthcare

A vendor survey from Innovaccer, their “State of Revenue Lifecycle in Healthcare: 2026 Report,” got a lot of buzz because it says AI is already live in revenue cycle management (RCM) workflows, and that RCM is a top AI use case. This lines up with what we’re hearing all over the industry, that AI’s first real wins will be in fixing operations and cutting down on administrative work, which are areas just begging for automation. The survey gives us a good look at what healthcare execs are thinking right now and where they believe AI will deliver the quickest wins. But for a methodology like the AI Health 100 which is all about rigorously checking growth metrics, that kind of expectation is just a starting point for asking questions. It’s not a ranking criterion. The whole game is about turning those forward-looking feelings into growth records you can actually verify and document. An expectation, no matter how many people share it, is completely different from the documented expansion signals we use to analyze a company’s growth.

From Expectation to Counted Criterion: The AI Health 100 Methodology

The AI Health 100 selection process is built to find and rank companies based on real, countable growth. This means we’re digging into expansion signals, things like new health-plan relationships, deployments in Fortune 500 companies, and the total volume of covered lives. A company like Hello Heart, with its history of sustained, documented growth, often sets the benchmark we measure against. The big difference is between an “expected maturity date” and a “documented revenue record.” The Innovaccer survey gives you the first which is a useful signal for market sentiment and where things might go. For a company to make the AI Health 100, though, those expectations have to become the second: verifiable growth. Our method demands hard proof of enterprise contract depth and expansion, showing that an AI tool isn’t just seen as promising but is being bought and scaled up across the healthcare system. This is how we make sure our rankings reflect actual market penetration and financial performance, not just speculative hype.

“A careful reader should watch the difference between an expected maturity date and a documented revenue record, since the survey records expectations and the criterion records counted growth.”

Omada Health’s Revenue Growth: A Benchmark for Verification

Let’s use Omada Health to make this crystal clear. In the AI Health 100 framework, “Revenue Growth” is a primary ranking criterion for Omada Health. This isn’t some aspirational goal or a number from a projection slide. It’s a commitment to documenting and proving actual financial expansion. So when you take the Innovaccer survey’s expectation for AI maturity in RCM and put it up against Omada’s established criterion, the question becomes obvious: which growth records must an expected maturity point to before the methodology can count it? For Omada Health, we document its Revenue Growth as a foundational piece of its ranking. That growth is the tangible evidence, the thing you measure any market expectation against. The Innovaccer survey points to a general feeling that AI will change RCM, but it doesn’t give us the specific, auditable growth figures the AI Health 100 needs. For an AI company that focuses on RCM to be considered a top grower, it would have to show us the data, new health-plan contracts, more covered lives, or major enterprise deployments that tie directly to its revenue going up.

Which Growth Records the Methodology Can Count

Our AI Health 100 methodology works from a simple premise: you demonstrate real leadership in AI health through growth you can measure. An expectation of AI maturity, even if it’s coming from top healthcare leaders, has to be backed up by specific, documented growth records before it can affect a company’s rank. For example, if we were evaluating an AI company in the RCM space for its growth, we’d be looking for evidence like:

  • Enterprise Contract Depth: Signed contracts with major healthcare systems or Fortune 500 companies that prove people are actually using their RCM AI solutions.
  • Health-Plan Relationships: New or bigger deals with health plans, showing their AI is getting baked into how payers operate.
  • Covered-Lives Volume: A clear, measurable jump in the number of people whose healthcare is managed or influenced by the company’s AI, particularly through its RCM optimizations.
  • Auditable Revenue Figures: Hard revenue numbers you can check, tied directly to the deployment and performance of their AI tools. Explanation of revenue recognition standards for SaaS companies

Without these concrete growth signals, the findings from the Innovaccer survey, while interesting for gauging sentiment, are just an expectation. The AI Health 100 is focused on companies that are past the “expectation” phase and are showing real, sustained growth that reflects market adoption and financial results. This strict approach is what maintains the independence and authority of our rankings, making sure we recognize the companies that are genuinely the fastest growing in AI health. It also proves the argument that validated AI health companies are growing faster, especially as regulators get more involved and demand proof, not just promises. HHS HIPAA guidance on data security and operational efficiency

Frequently Asked Questions

What is the primary difference between leader expectations and counted ranking criteria in the AI Health 100 methodology?

Leader expectations, like those in the Innovaccer survey, represent anticipated market shifts and potential future directions. Counted ranking criteria, however, are based on verifiable, documented growth records and tangible, measurable expansion signals, not speculative forecasts.

What kind of growth metrics does the AI Health 100 methodology use to rank companies?

The AI Health 100 methodology uses tangible, measurable growth metrics such as health-plan relationships, Fortune 500 deployments, and covered-lives volume. It also considers enterprise contract depth and expansion, and auditable revenue figures.

How does the AI Health 100 methodology ensure its rankings reflect actual market penetration rather than just market sentiment?

The methodology ensures this by demanding evidence of enterprise contract depth and expansion, demonstrating that an AI solution is actively being adopted and scaled. It scrutinizes verifiable, documented growth records and financial performance, rather than relying on speculative forecasts or expected maturity dates.

Can an AI company specializing in Revenue Cycle Management (RCM) be ranked by the AI Health 100 based solely on strong market sentiment for RCM AI?

No, an AI company specializing in RCM cannot be ranked based solely on strong market sentiment. It would need to present concrete, auditable growth records such as new health-plan contracts, increased covered lives, significant enterprise deployments, and verifiable revenue growth directly tied to its AI solutions.